Pancreatic Cancer Research

Clinical trialPhase 2Unknown

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Phase II Trial of Etoposide Plus Cisplatin Compared With Irinotecan Plus Cisplatin for First-line Treatment of Non-primary Pancreatic Metastatic and/or Unresectable Gastrointestinal Neuroendocrine Tumor G3 Type

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
1 June 2019
Listed end
1 June 2021
Enrollment
112 participants
Sites
0
Primary outcomes
Objective response rate (ORR); Progression-free Survival (PFS)
Sponsor type
Other government
Results posted
No
Last update
24 May 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The aim of this study is to investigate the efficacy, safety, and survival benefit of etoposide plus cisplatin and irinotecan plus cisplatin in first-line therapy of non-primary pancreatic metastatic and/or unresectable gastrointestinal neuroendocrine tumor G3 type. In addition, the investigators will explore the resistance mechanisms of gastrointestinal neuroendocrine tumor G3, and screen out biomarkers that can predict the efficacy of chemotherapy.

Detailed description public domain (ClinicalTrials.gov)

The prognosis of gastrointestinal neuroendocrine tumor G3 type patients who cannot be surgically resected is poor. The median overall survival (OS) is only 6-10 months, and the 3-year survival rate is less than 10%. Among the neuroendocrine tumors of the digestive system, only pancreatic neuroendocrine tumor has a standard treatment strategy, and there is a lack of prospective clinical research data on other gastrointestinal neuroendocrine tumors. According to the chemotherapy regimen of small cell lung cancer, etoposide plus cisplatin or irinotecan plus cisplatin is the choice of rescue therapy for advanced non-surgical or metastatic neuroendocrine tumor G3 type. However, prospective studies are needed to confirm whether there are differences in efficacy and safety between the two chemotherapy regimens. The aim of this study is to investigate the efficacy, safety, and survival benefit of etoposide plus cisplatin and irinotecan plus cisplatin in first-line therapy of non-primary pancreatic metastatic and/or unresectable gastrointestinal neuroendocrine tumor G3 type. In addition, the investigators will explore the resistance mechanisms of gastrointestinal neuroendocrine tumor G3, and screen out biomarkers that can predict the efficacy of chemotherapy.

Intervention public domain (ClinicalTrials.gov)

Drug: Etoposide. Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.

Intervention public domain (ClinicalTrials.gov)

Drug: Irinotecan. Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.

Arm public domain (ClinicalTrials.gov)

Etoposide plus Cisplatin (experimental): Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.

Arm public domain (ClinicalTrials.gov)

Irinotecan plus Cisplatin (experimental): Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days. When the investigator believes that the participant is not suitable for continued medication or the evaluation is progressive disease (PD) according to the RECIST 1.1 standard, the medication is over.

Primary outcome public domain (ClinicalTrials.gov)

Objective response rate (ORR). To compare objective response rate of the two arms from date of anti-cancer therapy until progression Time frame: up to 2 years.

Primary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS). From the first day of treatment until the date of first documented progression or date of death from any cause Time frame: up to 2 years.

Secondary outcome public domain (ClinicalTrials.gov)

Overall survival (OS). Time frame: up to 2 years.

Secondary outcome public domain (ClinicalTrials.gov)

Number of Participants with Treatment-related Adverse Events. Time frame: up to 2 years.

Secondary outcome public domain (ClinicalTrials.gov)

Assessment of Health-related quality of life. Time frame: up to 2 years.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * 1\. 18-75 years old, male or female. 2. Confirmed non-primary pancreatic metastatic and/or unresectable gastrointestinal neuroendocrine tumor G3 type patients by histopathological and imaging examinations. 3\. ECOG performance status 0-1. 4. Life expectancy ≥ 12 weeks. 5. A histological specimen can be provided for secondary testing. 6. According to the evaluation criteria of solid tumor efficacy (RESIST 1.1), there should be at least one measurable lesion (empty organs such as esophagus and stomach cannot be taken as the measurable lesion), and the measurable lesion should not have received local treatment such as radiotherapy (the lesion located in the previous radiotherapy area is also selected as the target lesion if the lesion progression is confirmed). 7\. Never received system treatment before, including cytotoxic drugs. For patients who have received adjuvant or neoadjuvant chemotherapy appears recurrence or metastasis more than 6 months from accepting the last dose of chemotherapy drugs can be screened. 8\. The main organ function meets the following criteria within 7 days before treatment: 1. Blood routine examination criteria (without blood transfusion within 14 days): hemoglobin (HB) ≥ 90g/L, the absolute value of neutrophils (ANC) ≥ 1.5 x 10\^9/L, platelet (PLT) ≥ 80 x 10\^9/L. 2. Biochemical examinations must meet the following criteria: total bilirubin (TBIL) ≤ 1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 x ULN, serum creatinine (Cr) ≤ 1.5 x ULN or creatinine clearance (CCR) ≥ 60 mL/min. 3. Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ normal low limit (50%). 9\. Fertile men and women must use effective contraception during the study period and within 6 months after the end of the study. 10\. Volunteered to participate in the study and signed an informed consent form. Exclusion Criteria: * 1.Patients exceeding or currently suffering from other malignant tumors within 5 years, except for cervical cancer in site, non-melanoma skin cancer and superficial bladder tumors (Ta (non-invasive tumor), Tis (in situ carcinoma), and T1 (tumor infiltrating basement membrane)); Patients with rapid progress within 3 months. 2\. History of gastrointestinal perforation and/or fistula within 6 months prior to the first administration. 3\. Patients who had received radiotherapy for tumor target lesions within 4 weeks before enrollment. 4\. History of …

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 112 participants (estimated).